Australian Injectable Drugs Handbook: 9th Edition updates
The Australian Injectable Drugs Handbook provides up-to-date and vital information on more than 500 injectable medicines and is an essential frontline resource ensuring patient safety and quality care.
Updated information and new monographs from the ninth edition can be found here.
Important new or changed information affecting administration, stability or compatibility. We recommend printing and replacing these pages in your hard copy of AIDH 9.
These new medicine monographs are added to AIDH 9 online. These monographs are not included in the print copy of AIDH 9, including reprints.
Andexanet alfa
Difelikefalin
Dostarlimab
Enfortumab vedotin
Faricimab
Fosnetupitant & palonosetron
Lenacapavir
Nivolumab & relatlimab
Progesterone
Tirzepatide
Vosoritide
March 2024
New drugs enfortumab vedotin, fosnetupitant and palonosetron (Akynzeo IV), nivolumab and relatlimab (Opdualag), progesterone, and tirzepatide.
Updated availability information for adalimumab, albumin, palifermin, and zoledronic acid.
Updated monitoring information for calcium salts
New CoPAT stability information for aztreonam, and cefiderocol
Updated administration advice for cetuximab
Minor editorial updates to ceftriaxone, and palonosetron
December 2023
Medicines shortage advice for benzathine benzylpenicillin
New drugs andexanet alfa, difelikefalin, dostarlimab, faricimab, lenacapavir, and vosoritide
Updated availability information for carboprost, daptomycin, and pemetrexed
Medicine shortages availability advice for dipyridamole, fludarabine, and mycobacterium bovis
Updated stability information for chorionic gonadotropin, dacarbazine, fulvestrant, natalizumab, and omalizumab
New compatibility information for oxycodone (Hartmann’s)
Addition of infusion equipment requirements for plitidepsin
Clarification of diluent for sodium valproate in status epilepticus
Clarification of soy as source of lecithin in benzathine benzylpenicillin (Bicillin-LA)
Updates to imipenem-cilastatin, and isavuconazole in response to user feedback
Summary of medicines requiring non-PVC and/or DEHP-free containers and infusion sets.
September 2023
Aciclovir (addition of powder presentation)
Phenylephrine (addition of Accord brand)
Aciclovir (addition of powder presentation)
Adamilumamb (addition of new biosimilars)
Albumin (Alburex 5% replaces Albumem 4%)
Aztreonam (new CoPAT stability information)
Benzathine benzylpenicillin (medicines shortage advice)
Calcium chloride and calcium gluconate (updated monitoring advice)
Carboprost (addition of Australian-registered products)
Cefiderocol (new CoPAT stability information)
Ceftriaxone (link to ANMF)
Cetuximab (updated administration advice)
Chorionic gonadotropin (updated stability)
Dacarbazine (updated stability)
Daptomycin (addition of Lupin, Pfizer products)
Dipyridamole (addition of S19A products)
Fludarabine (addition of S19A products)
Fulvestrant (updated stability)
Imipenem-cilastatin (updated concentration range)
Isavuconazole (addition of prodrug equivalence information)
Mycobacterium bovis (addition of S19A products)
Natalizumab (updated stability)
Omalizumab (updated stability)
Oxycodone (updated compatibility and stability)
Palifermin (updated presentation)
Palonosteron (addition of hypersensitivity reports)
Pemetrexed (addition of concentrated solution presentation)
Phenylephrine (addition of Accord brand)
Plitidepsin (clarification of container and infusion-set requirements)
Sodium valproate (updated compatibility)
Zoledronic acid (addition of new brand and indication for use)